Corcept Therapeutics (CORT) Receivables (2012 - 2026)

Corcept Therapeutics has disclosed Receivables across 15 years of filings, most recently posting $39.1 million for Q1 2026.

• Receivables for Q1 2026 came in at $39.1 million, down 51.17% year-over-year; the trailing twelve-month figure through Mar 2026 was $39.1 million (down 51.17% YoY), and the FY2025 annual result was $63.9 million, up 10.0% from the prior year.
• Receivables came in at $39.1 million for Q1 2026 at Corcept Therapeutics, down from $63.9 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $80.0 million in Q1 2025 to a low of $28.2 million in Q1 2022.
• The 5-year median for Receivables is $48.6 million (2023), against an average of $51.8 million.
• Across the five-year window, Receivables jumped 65.22% in 2023 and tumbled 51.17% in 2026, its largest moves.
• Corcept Therapeutics' Receivables stood at $45.1 million in 2022, then retreated by 4.96% to $42.8 million in 2023, then surged by 35.62% to $58.1 million in 2024, then gained by 10.0% to $63.9 million in 2025, then sank by 38.84% to $39.1 million in 2026.
• The last three Receivables figures came in at $39.1 million (Q1 2026), $63.9 million (Q4 2025), and $73.5 million (Q3 2025), per Business Quant data.